Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Piero Barbanti; Gabriella Egeo; Cinzia Aurilia; Florindo d’Onofrio; Maria Albanese; Ilaria Cetta; Paola Di Fiore; Maurizio Zucco; Massimo Filippi; Francesco Bono; Claudia Altamura; Stefania Proietti; Stefano Bonassi; Fabrizio Vernieri

doi:10.1186/s10194-022-01434-8

Corrigendum2022

Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri

Preprint2021

Fremanezumab in the Prevention of High-Frequency Episodic and Chronic Migraine: A 12-Week, Multicenter, Real-Life, Cohort Study (The FRIEND Study).

Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri

Article2022

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri

Article2021

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: Friend (fremanezumab in real world study), the first Italian multicenter, prospective real-life study

Luisa Fofi, Gabriella Egeo, Cinzia Aurilia, Carmelina Maria Costa, Claudia Altamura, Fabrizio Vernieri, Maria Albanese, Florindo d’Onofrio, Laura Di Clemente, Maurizio Zucco, Paola Di Fiore, Fabio Frediani, Roberta Messina, Bruno Colombo, Massimo Filippi, Francesco Bono, Lucia Manzo, Antonio Carnevale, Piero Barbanti, Stefania Proietti, Stefano Bonassi

Article2020

The First, Italian, Multicenter, Real-life Study with Erenumab in the Prevention of High Frequency Episodic and Chronic Migraine (2307)

Piero Barbanti, Cinzia Aurilia, Sabina Cevoli, Bruno Colombo, Fabio Frediani, Francesco Bono, Licia Grazzi, Domenico D’Amico, Antonio Salerno, B. Mercuri, Antonio Carnevale, Catello Vollono, Gabriella Egeo, Luisa Fofi, Claudia Altamura, Cármen Costa, Nicoletta Brunelli, Adriana Fallacara, Giulia Pierangeli, Valentina Favoni, Roberta Messina, Massimo Filippi, ,

Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Discussion(0)

Related publications

Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Fremanezumab in the Prevention of High-Frequency Episodic and Chronic Migraine: A 12-Week, Multicenter, Real-Life, Cohort Study (The FRIEND Study).

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: Friend (fremanezumab in real world study), the first Italian multicenter, prospective real-life study

The First, Italian, Multicenter, Real-life Study with Erenumab in the Prevention of High Frequency Episodic and Chronic Migraine (2307)